Skip to main content
Clinical Trials/IRCT2017090236033N1
IRCT2017090236033N1
Recruiting
Phase 2

Inquiry into pathologic response, complications, and overall survival in patients with locally advanced cervical cancer treated by neo-adjuvant chemotherapy and surgery

Vice-chancellery for Research of Mashhad University of Medicla Sciences0 sites30 target enrollmentTBD

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
locally advanced cervical cancer.
Sponsor
Vice-chancellery for Research of Mashhad University of Medicla Sciences
Enrollment
30
Status
Recruiting
Last Updated
8 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
8 years ago
Study Type
Interventional
Sex
Female

Investigators

Sponsor
Vice-chancellery for Research of Mashhad University of Medicla Sciences

Eligibility Criteria

Inclusion Criteria

  • Definitive pathologic diagnosis of squamous cell carcinoma; stages IB2, IIA2, and IIB based on the International Federation of Gynecology and Obstetrics classification; age between 18 and 70 years; World Health Organization performance of grade 2 or lower; adequate renal and hepatic function and bone marrow reserve (i.e., absolute granulocyte count equal to or above 2×103 per liter, platelet count equal to or above 100×103 per liter; hemoglobin equal to or above 8\.0 grams per deciliter, and glomerular filtration rate equal to or above 50\); feasibility of follow\-up in the ordered time; and informed consent.
  • Exclusion criteria: history of injection of chemotherapy drug in four weeks before study; serious comorbidities, for example, cardiac disease, poorly controlled diabetes mellitus, malignant hypertension, or bleeding tendency; overt infection; multiple concurrent active cancers; neuropathy grade 2 or greater; pregnancy; and history of serious hypersensitivity or allergy to cisplatin and paclitaxel.

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
Examine the patient's response and symptom improvement using the Integrated Approach to Symptom Management Model for the patients who has oral mucositis associated with hematologic cancer therapyhematological malignancies oral mucositis associated with cancer therapy
JPRN-UMIN000016948niversity of Hyogo20
Recruiting
Not Applicable
Examine the patient's response and symptom improvement using the intervention under the Integrated Approach to Symptom Management Model for the patients who has lymphedemalymphedema associated with cancer therapy
JPRN-UMIN000014469niversity of Hyogo20
Completed
Not Applicable
Examine the patient's response and symptom improvement using the Integrated Approach to Symptom Management Model for the patients who has skin toxicity associated with molecularly targeted drugskin toxicity associated with molecularly targeted drug
JPRN-UMIN000016947niversity of Hyogo20
Not yet recruiting
Not Applicable
Early oral feeding following free flap reconstruction for oral cancerOral cancerCancer - Head and neck
ACTRN12623001017617Illawarra Shoalhaven Local Health District38
Completed
Not Applicable
Evaluating the response to suspected disease outbreaks using a short message service (SMS) model14 priority diseases that require immediate reporting: adverse events following immunization, anthrax, cholera, Guinea worm, measles, neonatal tetanus, plague, Rift Valley fever, severe acute respiratory infections, viral hemorrhagic fever, yellow fever, and other (any public health event of national and international concerns).Infections and Infestations
ISRCTN79529838agasaki University (Japan)153